Hereditary Angioedema Therapeutic Market Size, Share, Growth Analysis, By Drug Class(C1-esterase inhibitor, Bradykinin B2 receptor antagonist), By Treatment Type(Prophylaxis, On-demand), By Route of Administration(Intravenous, Subcutaneous), By Region(North America, Europe) - Industry Forecast 2024-2031

The global market for Hereditary Angioedema Therapeutic was estimated to be valued at US$ XX Mn in 2021.

The global Hereditary Angioedema Therapeutic Market is estimated to grow at a CAGR of XX% by 2028.

The global Hereditary Angioedema Therapeutic Market is segmented on the basis of Drug Class, Treatment Type, Route of Administration, Region.

Based on region, the global Hereditary Angioedema Therapeutic Market is segmented into North America, Europe, Asia Pacific, Middle East & Africa and Latin America.

The key players operating in the global Hereditary Angioedema Therapeutic Market are BioCryst Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., Pharming Group N.V., CSL Limited, Shire Plc, Attune Pharmaceuticals, Inc., Adverum Biotechnologies, Inc., KalVista Pharmaceuticals, Inc..